Call for participation in the OPBC-05/EUBREAST-14R/ICARO study
Dear OPBC members
The OPBC-04/EUBREAST-06/OMA study was a great success. The OPBC and EUBREAST – with the help of several US top sites – managed to compare targeted axillary dissection with sentinel lymph node biopsy in > 1100 patients undergoing neoadjuvant chemotherapy for biopsy-confirmed node positive breast cancer. Giacomo presented the data orally at San Antonio in December, and the paper will be submitted soon.
In the next project, ICARO, we want to study patients with isolated tumor cells in the nodes after neoadjuvant chemotherapy: How are they treated? What is the likelihood of having additional positive nodes? What is the recurrence rate?
This time, we would ask you to obtain approval from your local research ethics committee. This, and the identification of eligible patients may take some time. However, the workload to collect clinical data will be limited, as given the rarity of this scenario, every center will only have a small number of cases.
We are confident that we will answer some important questions in this heavily understudied population and we aim at making this the largest series of patients with residual ITC’s ever published.
We would like to submit again for San Antonio (deadline mid-July 2023) and we aim at completing data collection by May 21th 2023. With our great networks, we can do it, but we cannot do it without you.
> Study synopsis
> 6-page protocol for submission to your ethical committee
If you are interested, please send an email to Giacomo Montagna (MontagnG@mskcc.org) and Walter Weber (walter.weber@usb.ch).
|
